X-154533012-CGTGGGGTCGTCCAGGTACCCTTTG-C
Variant summary
Our verdict is Pathogenic. The variant received 13 ACMG points: 13P and 0B. PM1PM4PP3PP5_Very_Strong
The NM_001360016.2(G6PD):c.957_980delCAAAGGGTACCTGGACGACCCCAC(p.Lys320_Thr327del) variant causes a disruptive inframe deletion change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. It is difficult to determine the true allele frequency of this variant because it is of type DEL_BIG, and the frequency of such variant types in population databases may be underestimated and unreliable. Variant has been reported in ClinVar as Likely pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. T319T) has been classified as Likely benign.
Frequency
Consequence
NM_001360016.2 disruptive_inframe_deletion
Scores
Clinical Significance
Conservation
Publications
- anemia, nonspherocytic hemolytic, due to G6PD deficiencyInheritance: XL Classification: DEFINITIVE, STRONG Submitted by: ClinGen, Ambry Genetics, Labcorp Genetics (formerly Invitae)
- G6PD deficiencyInheritance: XL Classification: DEFINITIVE Submitted by: ClinGen
- class I glucose-6-phosphate dehydrogenase deficiencyInheritance: XL Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 13 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_001360016.2. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| G6PD | NM_001360016.2 | MANE Select | c.957_980delCAAAGGGTACCTGGACGACCCCAC | p.Lys320_Thr327del | disruptive_inframe_deletion | Exon 9 of 13 | NP_001346945.1 | ||
| G6PD | NM_000402.4 | c.1047_1070delCAAAGGGTACCTGGACGACCCCAC | p.Lys350_Thr357del | disruptive_inframe_deletion | Exon 9 of 13 | NP_000393.4 | |||
| G6PD | NM_001042351.3 | c.957_980delCAAAGGGTACCTGGACGACCCCAC | p.Lys320_Thr327del | disruptive_inframe_deletion | Exon 9 of 13 | NP_001035810.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| G6PD | ENST00000393562.10 | TSL:1 MANE Select | c.957_980delCAAAGGGTACCTGGACGACCCCAC | p.Lys320_Thr327del | disruptive_inframe_deletion | Exon 9 of 13 | ENSP00000377192.3 | ||
| G6PD | ENST00000696421.1 | c.957_980delCAAAGGGTACCTGGACGACCCCAC | p.Lys320_Thr327del | disruptive_inframe_deletion | Exon 9 of 13 | ENSP00000512616.1 | |||
| G6PD | ENST00000369620.6 | TSL:5 | c.1095_1118delCAAAGGGTACCTGGACGACCCCAC | p.Lys366_Thr373del | disruptive_inframe_deletion | Exon 9 of 13 | ENSP00000358633.2 |
Frequencies
GnomAD3 genomes Cov.: 24
GnomAD4 genome Cov.: 24
ClinVar
Submissions by phenotype
Anemia, nonspherocytic hemolytic, due to G6PD deficiency Pathogenic:5
This variant, c.957_980del, results in the deletion of 8 amino acid(s) of the G6PD protein (p.Lys320_Thr327del), but otherwise preserves the integrity of the reading frame. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individual(s) with G6PD deficiency (PMID: 8241497, 16753852; internal data). ClinVar contains an entry for this variant (Variation ID: 10411). This variant disrupts a region of the G6PD protein in which other variant(s) (p.Gly321Glu) have been determined to be pathogenic (PMID: 30988594; internal data). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
Variant found in unrelated hemizygotes with deficiency and CNSHA (PS4_M, PP4). No detectable activity in red blood cells (PS3). Leads to deletion of eight amino acids (PM4). Not found in gnomAD (PM2). Post_P 0.997 (odds of pathogenicity 3158, Prior_P 0.1).
This G6PD variant (rs587776730) is absent from a large population dataset and has been reported to ClinVar. This Class I variant, sometimes referred to as "G6PD Nara", has been identified in three unrelated males with chronic-hemolytic anemia. This 24-bp deletion in exon 9 of the G6PD gene removes eight amino acids, leaving the rest of the protein in-frame. No measurable G6PD activity was detected in the hemolysate of a patient with this variant, and the partially purified protein was reported to be extremely thermolabile with rapid loss of activity. This variant was also identified in the patient's asymptomatic mother (JHG1850-2). Based on the available evidence, we consider this variant to be likely pathogenic.
not provided Pathogenic:3
PM2, PM4, PP4, PS4_supporting
The G6PD c.957_980del; p.Lys320_Thr327del variant (rs587776730), also known as G6PD Nara, is reported in the literature in an individual affected with G6PD deficiency (Hirono 1993). This variant deletes eight amino acids, leaving the rest of the protein in-frame. Functional analysis of hemolysate from an affected individual with this variant showed no detectable G6PD activity, and the variant protein was reported to be extremely thermolabile with rapid loss of residual enzyme activity (Hirono 1993). This variant is absent from general population databases (Exome Variant Server, Genome Aggregation Database), indicating it is not a common polymorphism. Based on available information, this variant is considered to be likely pathogenic. References: Hirono A et al. G6PD Nara: a new class 1 glucose-6-phosphate dehydrogenase variant with an eight amino acid deletion. Blood. 1993 Dec 1;82(11):3250-2.
In-frame deletion of 8 of amino acidsin a non-repeat region predicted to critically alter the protein; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 9674740, 8241497, 16753852)
Malaria, susceptibility to;C2720289:Anemia, nonspherocytic hemolytic, due to G6PD deficiency Pathogenic:1
Absent from controls (or at extremely low frequency if recessive) in Genome Aggregation Database, Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium.;Protein length changes due to in-frame deletions/insertions in a non-repeat region or stop-loss variants.;The prevalence of the variant in affected individuals is significantly increased compared to the prevalence in controls.;Patient's phenotype or family history is highly specific for a disease with a single genetic etiology.;Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at